Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has been assigned a $5.00 price target by equities research analysts at Roth Capital in a note issued to investors on Wednesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Roth Capital’s target price would indicate a potential upside of 71.29% from the stock’s current price.

Several other brokerages have also recently issued reports on CPRX. Zacks Investment Research cut Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Piper Jaffray Companies set a $6.00 price objective on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 7th. Finally, SunTrust Banks, Inc. restated a “buy” rating and set a $5.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Tuesday, September 5th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $5.50.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.01.

COPYRIGHT VIOLATION NOTICE: “Catalyst Pharmaceuticals, Inc. (CPRX) PT Set at $5.00 by Roth Capital” was first published by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/catalyst-pharmaceuticals-inc-cprx-pt-set-at-5-00-by-roth-capital/1675401.html.

In related news, insider Patrick J. Mcenany bought 20,000 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were bought at an average cost of $2.58 per share, for a total transaction of $51,600.00. Following the completion of the purchase, the insider now owns 4,471,026 shares of the company’s stock, valued at approximately $11,535,247.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 8.79% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Catalyst Pharmaceuticals by 11.3% in the second quarter. Vanguard Group Inc. now owns 3,348,549 shares of the biopharmaceutical company’s stock valued at $9,242,000 after buying an additional 340,614 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Catalyst Pharmaceuticals by 1,833.2% during the second quarter. JPMorgan Chase & Co. now owns 1,536,300 shares of the biopharmaceutical company’s stock valued at $4,240,000 after purchasing an additional 1,456,830 shares in the last quarter. State Street Corp raised its stake in shares of Catalyst Pharmaceuticals by 1,971.1% during the second quarter. State Street Corp now owns 938,195 shares of the biopharmaceutical company’s stock valued at $2,590,000 after purchasing an additional 892,895 shares in the last quarter. Kennedy Capital Management Inc. raised its stake in shares of Catalyst Pharmaceuticals by 298.5% during the second quarter. Kennedy Capital Management Inc. now owns 918,438 shares of the biopharmaceutical company’s stock valued at $2,535,000 after purchasing an additional 687,938 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Catalyst Pharmaceuticals by 620.9% during the second quarter. Northern Trust Corp now owns 802,566 shares of the biopharmaceutical company’s stock valued at $2,215,000 after purchasing an additional 691,238 shares in the last quarter. Institutional investors own 40.10% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.